HC Wainwright Predicts Envoy Medical Q1 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Envoy Medical in a report released on Tuesday, March 31st. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.14) for the quarter. HC Wainwright currently has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Envoy Medical’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.30) EPS.

Envoy Medical (NASDAQ:COCH) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.03 million.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Envoy Medical in a research note on Tuesday, January 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Envoy Medical has a consensus rating of “Hold” and an average price target of $6.00.

Envoy Medical Price Performance

Shares of COCH opened at $0.75 on Thursday. Envoy Medical has a 1-year low of $0.36 and a 1-year high of $1.91. The company has a market capitalization of $57.47 million, a P/E ratio of -0.61 and a beta of 2.07. The firm’s 50 day simple moving average is $0.68 and its 200 day simple moving average is $0.76.

Insider Activity

In other news, CFO Robert Potashnick acquired 212,500 shares of Envoy Medical stock in a transaction dated Thursday, February 12th. The shares were purchased at an average cost of $0.40 per share, for a total transaction of $85,000.00. Following the transaction, the chief financial officer owned 212,500 shares of the company’s stock, valued at $85,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Susan Kantor bought 96,150 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average price of $0.40 per share, with a total value of $38,460.00. Following the transaction, the director directly owned 174,037 shares in the company, valued at $69,614.80. The trade was a 123.45% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 20,433,650 shares of company stock valued at $8,173,460. 5.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of COCH. Focus Partners Wealth purchased a new position in shares of Envoy Medical during the first quarter worth approximately $276,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Envoy Medical in the 3rd quarter valued at $60,000. Finally, Geode Capital Management LLC boosted its stake in shares of Envoy Medical by 111.3% in the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock valued at $65,000 after purchasing an additional 51,813 shares in the last quarter. 8.59% of the stock is currently owned by institutional investors.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.